384
Participants
Start Date
August 3, 2021
Primary Completion Date
May 30, 2023
Study Completion Date
May 30, 2023
RSV MAT
Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
Placebo
Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
GSK Investigational Site, Soweto Gauteng
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Madrid
GSK Investigational Site, Boadilla Del Monte Madrid
GSK Investigational Site, TorrejOn Ardoz Madrid
GSK Investigational Site, Málaga
GSK Investigational Site, Birmingham
GSK Investigational Site, Dothan
GSK Investigational Site, Mobile
GSK Investigational Site, Prato
GSK Investigational Site, Missoula
GSK Investigational Site, Covington
GSK Investigational Site, Slidell
GSK Investigational Site, Lafayette
GSK Investigational Site, Plano
GSK Investigational Site, Arlington
GSK Investigational Site, Grapevine
GSK Investigational Site, Weatherford
GSK Investigational Site, Fort Worth
GSK Investigational Site, Houston
GSK Investigational Site, League City
GSK Investigational Site, Austin
GSK Investigational Site, Phoenix
GSK Investigational Site, Messina
GSK Investigational Site, Mysuru
GSK Investigational Site, Bhubaneswar
GSK Investigational Site, Caxias do Sul
GSK Investigational Site, RibeirAo PretoSP
GSK Investigational Site, Santa Maria
GSK Investigational Site, Halifax
GSK Investigational Site, Montreal
GSK Investigational Site, Helsinki
GSK Investigational Site, Perugia
GSK Investigational Site, Panama City
Lead Sponsor
GlaxoSmithKline
INDUSTRY